AstraZeneca share price falls harder than the market
The AstraZeneca share price closed at $164.52, down 2.59% and lagging the S&P 500's milder 0.19% decline as investors eyed July 27, 2026 earnings. Over the past month the stock has also trailed its sector, while London-listed shares remain in a technical downtrend. Broader U.S. indexes were softer but less sharp, with the Dow off 0.59% and the Nasdaq down 0.05% in the same session.
Key Takeaways
- AstraZeneca (AZN) finished at $164.52, a 2.59% drop that outpaced the S&P 500's 0.19% loss.
- Over the past month, AZN fell 3.45%, lagging a 6.06% gain in the Medical sector and a 0.55% rise in the S&P 500.
- Earnings are due July 27, 2026, with consensus EPS of $2.50 and revenue of about $15.31 billion.
- Zacks rates AZN a #3 (Hold); the forward P/E of 16.52 sits below the industry average of 18.8.
- On the LSE, shares traded near 12,670 GBp in a downtrend, with momentum still weak on technical gauges.
Why did the AstraZeneca share price fall more than the market?
According to Yahoo Finance reporting via Zacks, AZN's latest session decline was steeper than major U.S. benchmarks. The 2.59% drop left the stock well behind the S&P 500, Dow, and Nasdaq moves that day.
The underperformance is not just a one-day story. Over the past month, the AstraZeneca share price was down 3.45%, while the Medical sector rose 6.06% and the S&P 500 gained 0.55%. That gap is why traders are watching whether selling pressure eases into the earnings print.
What should investors watch in AstraZeneca's upcoming earnings?
AstraZeneca is scheduled to report on July 27, 2026. Consensus expects EPS of $2.50, up 14.68% from the year-ago quarter, and revenue of $15.31 billion, up about 5.9%.
For the full year, Zacks Consensus Estimates point to earnings of $10.22 per share and revenue of $63.15 billion—gains of roughly 11.57% and 7.51%, respectively. Over the past month, the Zacks Consensus EPS estimate edged down 0.29%, and the stock carries a Zacks Rank of #3 (Hold).
Investors tracking wealth moves across pharma and other assets can also browse more market coverage in our Net Worth & Wealth section.
How do AstraZeneca's valuation and technicals look now?
On valuation, AZN's forward P/E of 16.52 is below the Medical - Biomedical and Genetics industry average of 18.8. Its PEG ratio of 1.38 also compares with an industry PEG of 1.56, suggesting a relative discount on growth-adjusted terms. The industry holds a Zacks Industry Rank of 98, within the top 40% of more than 250 industries.
Separately, London-listed technicals painted a cautious picture. JournalArta noted a last price of 12,670.00 GBp, down 0.14% on the day, with the stock still below its 20-day and 50-day averages in a downtrend. RSI sat near 40.3 in neutral territory, while nearest support was cited around 12,364.00 GBp and resistance near 14,538.00 GBp, with a wait-and-see Hold technical verdict.
For investors, the near-term focus is whether earnings can reset sentiment after a steeper-than-market slide—or whether the chart's still-bearish short-term bias keeps pressure on the AstraZeneca share price.